Jagua Publication

Journal of Applied Health Sciences and Medicine, 6(5):9–19, 2026. DOI: 10.58614/jahsm652

Journal of Applied Health Sciences and Medicine

Journal homepage: https://jpub.org/journal-details.php?journal-id=39

ISSN (E): 2583-1887
Journal of Applied Health Sciences and Medicine

Research Article

Tolerance Lost: Pathways Linking Immune Regulation to Autoimmune Disorders

Zaid Nabeel Elia [1*], Nisreen Waleed Mustafa [2], Haween T. Nanakaly[3], Batool T. S. Al-Ali[4] and Najat J. Ahmed[1]

[1] *Department of Medical Laboratory Technology, Erbil Technical Health and Medical College, Erbil Polytechnic University, Erbil, Iraq.*
[2] *Clinical Pharmacy Department, College of Pharmacy, University of Basrah, Basrah, Iraq.*
[3] *College of Dentistry, Hawler Medical University, Kurdistan Region, Iraq.*
[*] *Corresponding author: m.zaid@epu.ed.iq*

Article Info

Keywords: *Immune tolerance, autoimmunity, Central tolerance, Peripheral tolerance, Regulatory T cells, Immunotherapy.*

Received: *20.04.2026;*
Accepted: *11.05.2026;*
Published: *18.05.2026*

Abstract

Immune tolerance is a fundamental immunological mechanism that enables discrimination between self and non-self antigens, thereby preventing autoimmunity. It is governed by central tolerance—operating in the thymus and bone marrow—and peripheral tolerance—mediated in secondary lymphoid organs and tissues. Central mechanisms eliminate or edit autoreactive lymphocytes during development, while peripheral tolerance relies on regulatory T cells (Tregs), anergy, clonal deletion, and immune privilege to suppress escaped autoreactive cells. Breakdown of these regulatory systems due to genetic predispositions, environmental triggers, or immune dysregulation leads to autoimmune disease. Understanding the interplay between tolerance and autoimmunity has advanced targeted therapies aimed at restoring immune homeostasis. Innovations such as Treg-based interventions and antigen-specific immunotherapies offer promising avenues for re-establishing tolerance and managing autoimmune conditions more precisely and effectively.

1. Introduction

Immune tolerance describes a state in which the immune system does not mount a harmful response against specific antigens that could otherwise stimulate immune activation [1]. It represents a fundamental physiological mechanism that allows the immune system to discriminate between self and non-self antigens, thereby preventing detrimental responses against host tissues and preserving tissue integrity [2]. Immunological tolerance is crucial not only for avoiding autoimmune diseases but also for accommodating commensal microbes, dietary antigens and maintaining maternal-fetal tolerance, where the fetus represents a semi-allogeneic graft tolerated by maternal immunity [3].

The phenomenon of immune tolerance was first observed by Ray D. Owen in 1945, who noted persistent blood cell chimerism in dizygotic twin calves sharing placental circulation, indicating an innate capacity of organisms to tolerate foreign cells. Although Owen did not use the term "immune tolerance," his findings paved the way for foundational experimental work by Sir Peter Medawar and Rupert Billingham in the 1950s. Medawar and colleagues demonstrated experimentally acquired tolerance by transplanting foreign tissues into neonatal mice, establishing key principles of acquired immune tolerance. Building upon these discoveries, Sir Frank Macfarlane Burnet proposed the clonal selection theory, suggesting that self-reactive lymphocytes are eliminated during early development—a concept now recognized as clonal deletion [2]. These pioneering contributions by Burnet and Medawar, honored with the Nobel Prize in Physiology or Medicine in 1960, laid the conceptual groundwork for the modern understanding of immune tolerance.

Mechanistically, immune tolerance involves complex cellular interactions and regulatory pathways orchestrated within primary and secondary lymphoid organs. It is generally categorized into two types based on anatomical site: central tolerance, which occurs in the thymus for T cells and in the bone marrow for B cells, and peripheral tolerance, which primarily takes place in secondary lymphoid organs and peripheral tissues [1, 3]. Central tolerance mechanisms encompass rigorous selection processes wherein immature T and B lymphocytes recognizing self-antigens undergo clonal deletion or receptor editing to minimize autoreactivity [2]. However, central mechanisms are not foolproof; self-reactive lymphocytes can escape deletion, necessitating additional peripheral tolerance mechanisms to maintain immune homeostasis [4].

Peripheral tolerance is enforced through multiple complementary mechanisms, including clonal anergy (functional unresponsiveness), deletion of autoreactive clones, immune privilege at certain anatomical sites, and active immune suppression mediated by regulatory T cells (Tregs) and immunoregulatory cytokines [3, 5]. Regulatory T cells expressing the transcription factor FoxP3 play a central role in peripheral tolerance, actively suppressing harmful immune responses against self-tissues and dampening inflammation [4].

Failure of immune tolerance mechanisms—whether due to genetic predisposition, environmental exposures, or dysregulation in immunoregulatory pathways—can lead to autoimmune responses characterized by immune-mediated tissue damage [6]. Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type 1 diabetes mellitus (T1DM), multiple sclerosis (MS), and inflammatory bowel diseases (IBD) arise from complex interactions between genetic factors, environmental triggers, and breakdowns in tolerance maintenance [3]. Recent studies have highlighted the role of epigenetic modifications, including DNA methylation and histone acetylation, in regulating immune-related gene expression, thereby contributing significantly to autoimmune pathogenesis [7].

Moreover, the immune system's tolerance mechanisms present inherent vulnerabilities. Chronic pathogens can exploit peripheral tolerance pathways to evade immune elimination and establish persistent infections. Likewise, tumors may induce peripheral immune tolerance within their microenvironment, enabling immune evasion and complicating the effective cancer immunotherapy [8].

Understanding the intricate balance between immune tolerance, autoimmunity, and immune regulation is therefore paramount. Elucidating these mechanisms not only advances insight into disease pathogenesis but also opens avenues for therapeutic interventions aimed at restoring immune tolerance and mitigating autoimmune and immune-mediated diseases.

2. Immune Response and Immunological Tolerance

Basic Principles of the Immune Response

The immune system is responsible for protecting organisms against invading pathogens, toxins, and malignant cells through a highly coordinated series of innate and adaptive responses. Innate immunity provides immediate, non-specific defense and also initiates adaptive immune responses by presenting antigens through antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells. The adaptive immune response is antigen-specific and involves lymphocytes—T and B cells—that recognize antigens via highly specialized receptors generated through gene rearrangement. This process leads to immunological memory and provides robust protection against future infections [1, 9].

Distinction Between Self and Non-Self Antigens

A critical function of the immune system is distinguishing self-antigens (the body's own molecules) from non-self antigens (foreign substances). The ability to discriminate between self and non-self is fundamental to the immune system's capacity to eliminate pathogens without damaging host tissues—a process known as immunological tolerance. Failure to maintain this distinction results in autoimmune reactions, wherein immune cells mistakenly target self-antigens, causing tissue damage and chronic inflammatory diseases [2, 8].

General Concepts and Significance of Immune Tolerance

Immunological tolerance refers to the mechanisms by which the immune system prevents harmful immune responses against self-antigens while allowing effective responses against pathogens. It operates through two fundamental processes: central tolerance, which occurs during lymphocyte development in primary lymphoid organs, and peripheral tolerance, which functions after mature lymphocytes enter circulation and secondary lymphoid tissues [9–11]. These tolerance mechanisms involve complex cellular interactions and molecular signaling pathways, including antigen recognition, co-stimulatory signals, cytokine environments, and regulatory immune cell functions [12, 13].

3. Mechanisms of Immunological Tolerance

Immune tolerance is the critical ability of the immune system to distinguish self from non-self, thus preventing harmful responses to self-tissues. Immunological tolerance is established through two main mechanisms: central and peripheral tolerance, as shown in Figures 1 and 2 [9, 14].

Central Tolerance

Central tolerance occurs in primary lymphoid organs—specifically, the thymus for T cells and the bone marrow for B cells—during early lymphocyte development. Immature lymphocytes that strongly recognize self-antigens undergo apoptosis (negative selection), receptor editing (primarily in B cells) or differentiate into regulatory subsets to prevent self-reactivity [14]. Within the thymus, developing T cells are exposed to self-antigens presented by thymic epithelial cells. T cells that strongly interact with these self-antigens are deleted via apoptosis, whereas T cells with moderate affinity interactions undergo positive selection, resulting in a self-tolerant T-cell repertoire [15]. However, central tolerance mechanisms are not entirely foolproof, allowing some autoreactive lymphocytes to reach peripheral tissues, requiring additional regulatory mechanisms known as peripheral tolerance [1].

T-cell Development and Selection in the Thymus

Within the thymus, developing T cells (thymocytes) undergo rigorous selection processes based on affinity interactions between their T-cell receptors (TCRs) and self-peptides presented by thymic epithelial cells in conjunction with major histocompatibility complex (MHC) molecules. T cells expressing receptors with moderate affinity interactions undergo positive selection, enabling their survival and maturation. In contrast, thymocytes with high-affinity interactions toward self-antigens are negatively selected and eliminated through apoptosis, thereby limiting self-reactivity [11, 16].

B-cell Development and Negative Selection in Bone Marrow

In the bone marrow, immature B cells also encounter self-antigens. Those B cells with high affinity toward self-antigens undergo receptor editing—altering their antigen receptor specificity—or are clonally deleted through apoptosis if receptor editing fails. This mechanism ensures the removal or modification of potentially autoreactive B cells before they enter peripheral circulation [9, 10].

Role of Autoimmune Regulator (AIRE)

The thymic expression of numerous tissue-specific self-antigens is controlled by the autoimmune regulator protein (AIRE), expressed predominantly by thymic medullary epithelial cells. AIRE ensures that developing T cells are exposed to a wide array of self-antigens from peripheral tissues, significantly contributing to the negative selection of autoreactive T cells. Deficiency or malfunction of AIRE results in incomplete central tolerance and increased susceptibility to autoimmune disorders [17].

Despite robust processes of central tolerance, some autoreactive lymphocytes inevitably escape into peripheral circulation, necessitating additional regulatory mechanisms collectively known as peripheral tolerance [18].



Figure 1: "Central tolerance mechanisms in primary lymphoid organs: In the thymus, T cells undergo positive and negative selection to eliminate self-reactive clones, guided in part by AIRE-mediated antigen presentation." Concurrently, B cells in the bone marrow undergo receptor editing or clonal deletion to ensure self-tolerance. These processes collectively shape a self-tolerant lymphocyte repertoire before peripheral circulation [14]

Peripheral Tolerance

Peripheral tolerance mechanisms function beyond primary lymphoid organs, actively regulating self-reactive lymphocytes that have migrated to peripheral circulation, lymph nodes, spleen, and other secondary lymphoid tissues. Mechanisms of peripheral tolerance include clonal deletion, anergy, immunological ignorance, and regulatory T cell-mediated suppression, as shown in Figure 3 [14].

Clonal Deletion and Anergy

Peripheral clonal deletion refers to the apoptosis-mediated elimination of mature self-reactive lymphocytes that escape central tolerance and become activated in the periphery. Anergy, a key peripheral tolerance mechanism, describes a state of T cell unresponsiveness resulting from antigen recognition in the absence of co-stimulatory signals. In this state, T cells remain alive but are functionally inactivated, preventing them from mounting immune responses against self-antigens. This process is crucial for maintaining immune homeostasis and preventing autoimmunity [1, 4, 9].



Figure 2: "Central and peripheral tolerance to self-antigens. Central tolerance: Immature lymphocytes specific for self-antigens may encounter these antigens in the generative (central) lymphoid organs and are deleted; B lymphocytes may change their specificity (receptor editing); and some T lymphocytes develop into regulatory T cells. Some self-reactive lymphocytes may complete their maturation and enter peripheral tissues. Peripheral tolerance: mature self-reactive lymphocytes may be inactivated or deleted by encounter with self-antigens in peripheral tissues or suppressed by regulatory T cells., cited by [14]

Immunological Ignorance and Immune Privilege Sites

Immunological ignorance arises when self-antigens are either sequestered in immunologically privileged sites or expressed at concentrations too low to trigger lymphocyte activation. In such cases, potentially self-reactive lymphocytes remain unaware of these antigens and do not initiate an immune response. Organs such as the brain, eye, testis, and placenta exhibit immune privilege by limiting antigen presentation and immune cell infiltration through both structural and molecular mechanisms. These features contribute significantly to the maintenance of peripheral tolerance by preventing unnecessary inflammatory responses [1, 9].

Role of Dendritic Cells in Peripheral Tolerance

Dendritic cells (DCs) play a pivotal role in peripheral tolerance due to their ability to present antigens in the absence of inflammation. Immature or tolerogenic DCs promote lymphocyte anergy or differentiation into regulatory subsets, thereby suppressing auto-reactivity and inflammation. Tolerogenic DCs modulate immune responses through production of anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-β), critically influencing peripheral immune homeostasis [19].

Homeostatic Regulation and Regulatory T Cells (Tregs)

Specialized regulatory T cells (Tregs), predominantly characterized by the expression of the transcription factor FoxP3, are essential mediators of peripheral tolerance. They actively suppress autoreactive immune responses through multiple mechanisms, including the secretion of immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), cytotoxic T-lymphocyte antigen 4 (CTLA-4)-dependent modulation of co-stimulatory signaling, and direct inhibitory cell–cell interactions. Functional impairment or numerical deficiency of Tregs is strongly associated with various autoimmune diseases, highlighting their critical role in immune homeostasis [9, 18, 20].

Collectively, central and peripheral tolerance mechanisms tightly regulate immune reactivity against self, maintaining homeostasis, preventing autoimmunity, and preserving normal physiological functions [1, 4, 14].



Figure 3: Peripheral tolerance prevents autoimmunity by eliminating, inactivating, or suppressing self-reactive lymphocytes in peripheral tissues through mechanisms such as clonal deletion, anergy, immune privilege, tolerogenic dendritic cells, and regulatory T cells (Tregs), cited by [14]

4. Immune Regulation at the Interface of Tolerance and Autoimmunity

Regulatory Immune Cells

Regulatory immune cells play vital roles in maintaining immune homeostasis. These include regulatory T cells (Tregs), regulatory B cells (Bregs), and myeloid-derived suppressor cells (MDSCs).

Regulatory T Cells (Tregs)

Regulatory T Cells (Tregs) are central to the suppression of autoreactive lymphocytes and the maintenance of peripheral tolerance. Tregs are classified into thymically derived Tregs (tTregs) and peripherally induced Tregs (pTregs), both defined by expression of the transcription factor FoxP3. They exert their suppressive functions via secretion of anti-inflammatory cytokines such as IL-10, TGF-β, and IL-35, as well as through cell-contact-dependent mechanisms involving molecules like CTLA-4 and PD-1. Deficiency or dysfunction of Tregs is associated with various autoimmune disorders, including type 1 diabetes, systemic lupus erythematosus, and multiple sclerosis [1, 20–22].

Regulatory B Cells (Bregs)

Regulatory B Cells (Bregs) contribute to immune suppression primarily through IL-10 production, modulating T cell responses and limiting inflammation. Their dysfunction is also implicated in autoimmunity [1, 4].

Myeloid-Derived Suppressor Cells (MDSCs)

Myeloid-Derived Suppressor Cells (MDSCs) are a heterogeneous group of immature myeloid cells that suppress T cell activity via arginase production, nitric oxide, and reactive oxygen species. MDSCs have been increasingly recognized in autoimmune contexts, although their role is more established in cancer [23].

Cytokines and Chemokines

Cytokines and chemokines are key modulators of immune cell recruitment and differentiation. Anti-inflammatory cytokines such as IL-10 and TGF-β are vital for the suppression of immune responses and the maintenance of self-tolerance. Dysregulated cytokine production, including overexpression of pro-inflammatory cytokines like IL-6, TNF-α, or IL-17, can disturb immune equilibrium and promote autoimmune pathology [4, 22, 23].

Chemokines, including CCL2, CCL5, and CXCL10, play essential roles in trafficking immune cells to inflammatory or tolerogenic environments. Aberrant expression of these chemokines has been linked to autoimmune disease progression [22].

Immunological Checkpoints and Therapeutic Implications

Immune checkpoints act as molecular brakes to prevent uncontrolled T cell activation. CTLA-4 and PD-1 are well-studied inhibitory receptors that contribute to the regulation of peripheral tolerance. CTLA-4 competes with CD28 for binding B7 ligands, while PD-1 inhibits TCR signaling upon engagement with PD-L1/PD-L2. These molecules are not only central to maintaining self-tolerance but are also critical targets in immunotherapy [4, 9, 22].

Checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies, have revolutionized cancer treatment but can induce immune-related adverse events (irAEs), including autoimmune-like diseases. This duality highlights the role of checkpoints in both cancer surveillance and autoimmune regulation [9, 22, 23].

Collectively, these regulatory mechanisms maintain immune system balance, preventing excessive responses and enabling protective immunity.

5. Breaking Immune Tolerance: Transition to Autoimmunity

The maintenance of immune tolerance is critical to preventing autoimmunity. This tolerance is orchestrated through central and peripheral tolerance mechanisms that regulate lymphocyte development and function. Central tolerance eliminates autoreactive T and B cells during their maturation in the thymus and bone marrow, while peripheral tolerance mechanisms—including anergy, immune suppression by regulatory T cells (Tregs), and activation-induced cell death—control potentially autoreactive cells that escape central deletion. Autoimmune diseases emerge when these checkpoints are compromised, enabling the activation and expansion of autoreactive lymphocytes [1, 4, 9].

Key Pathways Involved in Tolerance Breakdown

Multiple immunological pathways converge in the breakdown of tolerance. One critical pathway involves the dysregulation of Tregs, which are central to maintaining peripheral tolerance by suppressing effector T cell activity and promoting tissue homeostasis. A reduction in Treg number or function has been observed in various autoimmune disorders, such as type 1 diabetes and systemic lupus erythematosus. In addition, aberrant antigen presentation by dendritic cells and defective apoptosis of autoreactive cells contribute to immune dysregulation. Cytokine imbalances—particularly increased levels of proinflammatory cytokines like IL-6, IL-17, and IFN-γ—further amplify autoreactive responses [24].

Molecular and Cellular Mechanisms Leading to Autoimmunity

The initiation of autoimmune responses involves both innate and adaptive immune components. Molecular mechanisms include loss of self-antigen tolerance, increased antigen presentation, and epitope spreading, where new self-antigens are revealed following initial immune attacks. On the cellular level, autoreactive CD4+ T helper cells play a pivotal role by providing help to autoreactive B cells, promoting autoantibody production. Dysregulated B cell activation leads to the formation of immune complexes that deposit in tissues, causing inflammation and damage. Furthermore, failures in negative selection during lymphocyte development, and abnormal expression of co-stimulatory molecules (e.g., CD28, CD80/86), drive autoimmune responses [2, 25, 26].

Interactions Between Genetic Predispositions and Environmental Triggers

Autoimmunity results from a complex interplay between genetic susceptibility and environmental exposures. Genetic factors—particularly polymorphisms in the HLA gene complex—strongly influence the risk of developing autoimmune diseases. For example, HLA-DRB1*04:01 is associated with rheumatoid arthritis, while HLA-DR3/4 increases susceptibility to type 1 diabetes. Mutations or polymorphisms in genes regulating immune checkpoints (e.g., CTLA4, PTPN22, IL2RA) further alter immune thresholds and tolerance. However, genetics alone is not sufficient to cause disease; environmental factors such as viral infections (e.g., Epstein-Barr virus in multiple sclerosis), gut dysbiosis, and exposure to certain drugs or toxins act as catalysts for disease onset by promoting inflammation or inducing molecular mimicry [22, 25].

One critical mechanism connecting infections to autoimmunity is molecular mimicry, where pathogen-derived antigens closely resemble host proteins. The immune system, in mounting a defense against the pathogen, inadvertently attacks similar self-antigens. This phenomenon has been observed in Guillain-Barré syndrome (linked to Campylobacter jejuni) and in rheumatic heart disease (due to Streptococcus pyogenes). Molecular mimicry, especially when coupled with genetic predisposition and defective peripheral tolerance, represents a major pathway by which infections may precipitate autoimmune diseases [27].

The shift from immune tolerance to autoimmunity results from complex interactions among genetic susceptibility (e.g., HLA polymorphisms), environmental triggers (e.g., infections, toxins), and immune dysregulation. Mechanisms such as molecular mimicry, epitope spreading, impaired regulatory T cell function, and defective central and peripheral tolerance collectively promote autoimmune diseases. Clarifying these pathways is essential for developing targeted therapies to restore immune tolerance.

The pathways by which genetic and environmental factors disrupt immune tolerance—ultimately leading to autoimmunity—are clearly illustrated in Figure 4 [14]. This figure summarizes how alterations in tolerance mechanisms, Treg dysfunction, cytokine imbalance, and molecular mimicry result in the activation of autoreactive lymphocytes and tissue injury.



Figure 4: Breaking Immune Tolerance: Transition to Autoimmunity. This diagram illustrates the multi-step breakdown of immune tolerance leading to autoimmune disease. Genetic predispositions (e.g., HLA variants) and environmental triggers (e.g., infections, toxins) disrupt immune checkpoints such as CTLA-4 and PD-1, contributing to the failure of self-tolerance. Antigen-presenting cells (APCs) present self-antigens, activating self-reactive T cells. These T cells then assist in activating self-reactive B cells, which differentiate into plasma cells that secrete autoantibodies. Autoantibodies form immune complexes and recruit effector cells like neutrophils, amplifying inflammation. This chronic immune activation culminates in tissue injury, the hallmark of autoimmune pathogenesis, cited by [14]

6. Etiology and Risk Factors for Autoimmune Diseases

Genetic Risk Factors

- **Role of HLA Genes (HLA and Non-HLA Genetic Associations)**

  Genetic predisposition significantly influences susceptibility to autoimmune diseases, primarily mediated through the Human Leukocyte Antigen (HLA) complex. HLA genes encode proteins involved in antigen presentation, critical in dictating immune recognition and response to self and non-self antigens. Specific HLA alleles strongly correlate with autoimmune disorders, such as HLA-DR3 and HLA-DR4 in Type 1 Diabetes Mellitus (T1DM), and HLA-DRB1 in rheumatoid arthritis (RA) [28, 29]. While certain alleles predispose individuals to autoimmune diseases, other HLA variants confer protective effects, exemplifying the dual role of these genetic factors in immune regulation [30].
- **Non-HLA Genetic Factors (Genetic Susceptibility versus Protective Alleles)**

  Beyond the HLA complex, genome-wide association studies (GWAS) have identified numerous non-HLA genetic factors contributing to autoimmune susceptibility, highlighting the polygenic and multifactorial nature of these diseases. Genes involved in immune regulation, including those influencing cytokine signaling pathways, regulatory T cell function, and apoptosis, significantly modulate disease risk [31]. Protective alleles, though comparatively less studied, have been recognized; examples include certain polymorphisms in CTLA-4 and PTPN22 genes, which can either increase or decrease the risk of developing autoimmune conditions, depending on the allele variant [30]. Animal models, notably non-obese diabetic (NOD) and NZB/NZW lupus-prone mice, have provided substantial insights into genetic susceptibility mechanisms due to their close genetic homology with human autoimmune conditions [31].

  Beyond the HLA complex, genome-wide association studies (GWAS) have identified numerous non-HLA genetic factors contributing to autoimmune susceptibility, underscoring the polygenic and multifactorial nature of these diseases. Genes involved in immune regulation, including those influencing cytokine signaling pathways, regulatory T cell function, and apoptosis, significantly modulate disease risk [22]. Protective alleles, though comparatively less studied, have been recognized; examples include certain polymorphisms in CTLA-4 and PTPN22 genes, which can either increase or decrease the risk of developing autoimmune conditions depending on the allele variant [30]. Animal models, notably non-obese diabetic (NOD) and NZB/NZW lupus-prone mice, have provided substantial insights into genetic susceptibility mechanisms due to their close genetic homology with human autoimmune conditions [3].

Environmental Risk Factors

- **Infections and Molecular Mimicry**

  Environmental triggers, especially infections, significantly influence autoimmune disease initiation and progression through

mechanisms such as molecular mimicry. In molecular mimicry, microbial antigens structurally resemble host antigens, leading to cross-reactive immune responses that inadvertently target self-tissues. A notable example is the coxsackievirus infection, which selectively infects pancreatic β-cells, leading to autoimmune diabetes through immune-mediated destruction of the insulin-producing cells [32]. This process is further supported by evidence from experimental animal models where viral infections consistently induce chronic autoimmune inflammation [33, 34].

- **Lifestyle, Dietary, and Chemical Exposures**
  Lifestyle and environmental exposures, including diet, sunlight, medications, and various chemicals, significantly modulate autoimmune risk. Ultraviolet radiation exposure exacerbates systemic lupus erythematosus (SLE) by inducing cellular apoptosis and enhancing the release of nuclear autoantigens, thereby compromising immune tolerance [35]. Similarly, certain medications and chemical compounds can modify self-antigens, converting them into novel immunogenic epitopes that break immune tolerance and trigger autoimmune responses [34, 36].
- **Impact of the Microbiome in Tolerance and Autoimmunity**
  The gut microbiome plays a crucial role in maintaining immune homeostasis and tolerance. Dysbiosis, or alterations in gut microbial composition, can significantly enhance susceptibility to autoimmune diseases such as inflammatory bowel disease (IBD), multiple sclerosis (MS), and RA. Microbiota-derived metabolites and bacterial antigens profoundly influence regulatory T cell (Treg) differentiation and functional capacity, underscoring the essential role of microbial signals in immune regulation and autoimmune disease progression [34, 37].

Interplay Between Genetic and Environmental Influences (Gene-Environment Interactions in Autoimmunity)

Autoimmune diseases typically arise from intricate interactions between genetic predispositions and environmental stimuli, highlighting the complex nature of autoimmune etiology. Gene-environment interactions are evident in diseases such as celiac disease, where gluten ingestion triggers autoimmune responses exclusively in genetically predisposed individuals carrying specific HLA haplotypes [38].

Central to this interaction are regulatory T cells (Tregs), particularly CD4+CD25+Foxp3+ cells, which play critical roles in maintaining peripheral tolerance. Mutations or functional impairments in the Foxp3 gene cause severe autoimmune syndromes, exemplified by immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome and mouse models such as 'scurfy' mice [20, 39]. Furthermore, optimal Treg function and differentiation depend on environmental signals, notably those derived from the gut microbiota, emphasizing the profound influence of environmental factors on genetic predispositions. Germ-free animal studies have demonstrated that the absence of microbiota-derived signals significantly impairs Treg-mediated peripheral tolerance, leading to severe autoimmune pathology [12, 22].

Additionally, psychological stress and hormonal influences further demonstrate how environmental stimuli can modulate genetic susceptibility through neuroendocrine-immune interactions, although precise mechanisms continue to be elucidated [40, 41]. A comprehensive understanding of these intricate gene-environment interactions will ultimately enhance our capability to develop targeted, personalized interventions for autoimmune diseases.

7. Therapeutic Strategies to Restore Immune Tolerance

Current and Emerging Therapies Aimed at Tolerance Restoration

Restoring immune tolerance in autoimmune diseases represents a critical therapeutic goal, aiming to achieve sustained remission or even cure by reestablishing the immune system's ability to distinguish self from non-self antigens. Current and emerging therapeutic strategies primarily involve immunosuppressive and biological agents, as well as tolerance induction therapies that are more antigen-specific and aim at harnessing regulatory mechanisms intrinsic to the immune system [42].

Immunosuppressive and Biological Agents

Conventional immunosuppressive drugs, such as corticosteroids, methotrexate, and cyclophosphamide, have traditionally been used to manage autoimmune diseases by broadly dampening immune responses. More targeted biological therapies, including monoclonal antibodies such as rituximab (anti-CD20), abatacept (CTLA4-Ig), and tocilizumab (anti-IL-6 receptor), have emerged to selectively inhibit specific immune pathways involved in disease pathogenesis. These targeted agents reduce systemic immunosuppression, improve patient outcomes, and minimize adverse effects [43]. However, despite notable clinical improvements, these agents rarely induce long-term tolerance, requiring continuous treatment and thus posing risks related to chronic immunosuppression such as infections and malignancies [44].

Tolerance Induction Therapy

Recent advances have shifted the focus toward antigen-specific therapies and regulatory T-cell (Treg)-based approaches, designed explicitly to reprogram immune responses and induce lasting tolerance.

Antigen-specific therapies target precise autoantigens to recalibrate the immune system's specificity and restore tolerance. Approaches include peptide immunotherapy, altered peptide ligands, and nanoparticle-based antigen delivery systems designed to modulate antigen presentation and reduce autoimmune reactivity without broad immune suppression [45]. Clinical trials in multiple sclerosis and type 1 diabetes have shown promising outcomes, demonstrating safety and evidence of immunological tolerance induction [46].

Treg-based therapies leverage the natural immunoregulatory capacity of Tregs, essential in maintaining peripheral tolerance. Approaches include adoptive transfer of expanded autologous Tregs and in vivo expansion via low-dose IL-2 therapy or IL-2 muteins specifically engineered for selective Treg stimulation [31]. Clinical trials using adoptive Treg therapies in transplantation and type 1 diabetes indicate favorable safety profiles and early evidence of efficacy, highlighting the potential to achieve long-term immune tolerance without significant immunosuppression [47].

Successes, Limitations, and Ongoing Clinical Trials

While emerging therapies exhibit substantial potential, achieving sustained clinical tolerance remains challenging. Immunosuppressive therapies effectively control symptoms but rarely achieve complete immune tolerance, requiring lifelong administration and exposing patients to significant side effects. Conversely, antigen-specific and Treg-based therapies provide the possibility of true tolerance induction but face technical challenges, including Treg stability, specificity, and the risk of inadvertent immune activation [45, 48].

Ongoing clinical trials continue to refine therapeutic protocols, focusing on optimizing dose regimens, identifying precise antigenic targets, and enhancing regulatory T cell function and persistence. Examples include the Phase II and III clinical trials investigating antigen-specific nanoparticles for type 1 diabetes (ClinicalTrials.gov NCT04590872) and low-dose IL-2 regimens for autoimmune diseases like lupus and rheumatoid arthritis (ClinicalTrials.gov NCT04864561, NCT04371419).

Continued advancements in precision medicine and immunological insights hold the promise of transforming therapeutic strategies toward effective, safe, and lasting restoration of immune tolerance in autoimmune diseases.

8. Conclusion

Maintaining immune tolerance is fundamental for preventing autoimmune disorders, necessitating tightly coordinated central and peripheral tolerance mechanisms. Central tolerance, mediated through selective processes within the thymus and bone marrow, is complemented by peripheral regulatory controls, notably involving regulatory T cells (Tregs), dendritic cells, and immune checkpoints. Disruptions to these intricate regulatory networks due to genetic susceptibility, environmental triggers, or immune dysregulation facilitate the transition from tolerance to autoimmune pathogenesis. Recent advances in antigen-specific immunotherapies and regulatory T-cell-based interventions present promising avenues for restoring tolerance, highlighting the potential for more targeted, effective, and safer therapeutic strategies. However, significant challenges remain in optimizing the specificity, stability, and efficacy of these therapies. Future research focusing on elucidating tolerance mechanisms and refining targeted therapeutic approaches holds substantial promise for improving clinical management and achieving durable remission in autoimmune diseases.

Article Information

Disclaimer (Artificial Intelligence): The author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.), and text-to-image generators have been used during writing or editing of manuscripts.

Competing Interests: Authors have declared that no competing interests exist.

References

[1] F. Shirafkan, L. Hensel, and K. Rattay. Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis. *Frontiers in Immunology*, 15:1339714, 2024.

[2] F. Yasmeen, R. Hassan Pirzada, B. Ahmad, B. Choi, and S. Choi. Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies. *International Journal of Molecular Sciences*, 25(14):7666, 2024.

[3] Y. Song, J. Li, and Y. Wu. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. *Signal Transduction and Targeted Therapy*, 9(1):263, 2024.

[4] G. Sogkas et al. Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. *Cellular Molecular Immunology*, 18(5):1122–1140, 2021.

[5] N. Cheru, D. A. Hafler, and T. S. Sumida. Regulatory T cells in peripheral tissue tolerance and diseases. *Frontiers in Immunology*, 14: 1154575, 2023.

[6] S. Mu et al. Autoimmune disease: A view of epigenetics and therapeutic targeting. *Frontiers in Immunology*, 15:1482728, 2024.

[7] R. Mazzone et al. The emerging role of epigenetics in human autoimmune disorders. *Clinical epigenetics*, 11:1–15, 2019.

[8] K. V. Tarbell and J. G. Egen. Breaking self-tolerance during autoimmunity and cancer immunity: myeloid cells and type I IFN response regulation. *Journal of Leukocyte Biology*, 103(6):1117–1129, 2018.

[9] X. Meng et al. Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells. *Asia Pacific Allergy*, 13(4): 175–186, 2023.

[10] D. Nemazee. Mechanisms of central tolerance for B cells. *Nature Reviews Immunology*, 17(5):281–294, 2017.

[11] L. Klein, E. A. Robey, and C.-S. Hsieh. Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation. *Nature Reviews Immunology*, 19(1):7–18, 2019.

[12] K. Wing and S. Sakaguchi. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. *Nature immunology*, 11 (1):7–13, 2010.

[13] P. Grover, P. N. Goel, and M. I. Greene. Regulatory T cells: regulation of identity and function. *Frontiers in immunology*, 12:750542, 2021.

[14] A. K. Abbas, A. H. Lichtman, and S. Pillai. *Basic immunology: Functions and disorders of the immune system, 6e: Sae-E-Book*. Elsevier, Health Sciences, 2019.

[15] L. Klein et al. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). *Nature Reviews Immunology*, 14(6):377–391, 2014.

[16] K. M. Ashby and K. A. Hogquist. Author Correction: A guide to thymic selection of T cells. *Nature Reviews Immunology*, 23(10):697, 2023.

[17] M. S. Anderson and M. A. Su. AIRE expands: new roles in immune tolerance and beyond. *Nature Reviews Immunology*, 16(4): 247–258, 2016.

[18] S. Dikiy and A. Y. Rudensky. Principles of regulatory T cell function. *Immunity*, 56(2):240–255, 2023.

[19] C. Audiger et al. The importance of dendritic cells in maintaining immune tolerance. *The Journal of Immunology*, 198(6):2223–2231, 2017.

[20] J. B. Wing, A. Tanaka, and S. Sakaguchi. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. *Immunity*, 50(2):302–316, 2019.

[21] M. Hardtke-Wolenski and S. Landwehr-Kenzel. Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both? *Molecular and Cellular Pediatrics*, 11(1):3, 2024.

[22] A. M. Hocking and J. H. Buckner. Genetic basis of defects in immune tolerance underlying the development of autoimmunity. *Frontiers in Immunology*, 13:972121, 2022.

[23] A. Long, A. Kleiner, and R. J. Looney. Immune dysregulation. *Journal of Allergy and Clinical Immunology*, 151(1):70–80, 2023.

[24] M. Dominguez-Villar and D. A. Hafler. Regulatory T cells in autoimmune disease. *Nature immunology*, 19(7):665–673, 2018.

[25] L. Sun et al. T cells in health and disease. *Signal transduction and targeted therapy*, 8(1):235, 2023.

[26] N. Gholijani, G. Daryabor, and F. R. Kahmini. T cell-Intrinsic Peripheral Tolerance: A Checkpoint Target to Treat Autoimmunity. *Journal of Cellular Immunology*, 6(2):87–97, 2024.

[27] M. F. Cusick, J. E. Libbey, and R. S. Fujinami. Molecular mimicry as a mechanism of autoimmune disease. *Clinical reviews in allergy immunology*, 42:102–111, 2012.

[28] J. A. Todd. Etiology of type 1 diabetes. *Immunity*, 32(4):457–467, 2010.

[29] J. A. Noble and A. M. Valdes. Genetics of the HLA region in the prediction of type 1 diabetes. *Current diabetes reports*, 11:533–542, 2011.

[30] M. Gutierrez-Arcelus, S. S. Rich, and S. Raychaudhuri. Autoimmune diseases—connecting risk alleles with molecular traits of the immune system. *Nature Reviews Genetics*, 17(3):160–174, 2016.

[31] J. A. Bluestone et al. Opportunities for Treg cell therapy for the treatment of human disease. *Frontiers in immunology*, 14:1166135, 2023.

[32] C. M. Filippi and M. G. von Herrath. Viral trigger for type 1 diabetes: pros and cons. *Diabetes*, 57(11):2863, 2008.

[33] M. S. Horwitz et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. *Nature medicine*, 4(7):781–785, 1998.

[34] M. Chowaniec, A. Kawalec, and K. Pawlas. Environmental risk factors in autoimmune diseases: a review of literature. *Medycyna Środowiskowa-Environmental Medicine*, 20(3):12–20, 2017.

[35] A. Kuhn and M. Bijl. Pathogenesis of cutaneous lupus erythematosus. *Lupus*, 17(5):389–393, 2008.

[36] L. Wang, F. S. Wang, and M. E. Gershwin. Human autoimmune diseases: a comprehensive update. *Journal of internal medicine*, 278 (4):369–395, 2015.

[37] K. Honda and D. R. Littman. The microbiota in adaptive immune homeostasis and disease. *Nature*, 535(7610):75–84, 2016.

[38] J. Ludvigsson and P. Green. Clinical management of coeliac disease. *Journal of internal medicine*, 269(6):560–571, 2011.

[39] C. L. Bennett et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nature genetics*, 27(1):20–21, 2001.

[40] S. C. Segerstrom and G. E. Miller. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. *Psychological bulletin*, 130(4):601, 2004.

[41] I. R. Mackay. Tolerance and autoimmunity. *Bmj*, 321(7253):93–96, 2000.

[42] Y. R. Mohseni et al. The future of regulatory T cell therapy: promises and challenges of implementing CAR technology. *Frontiers in immunology*, 11:1608, 2020.

[43] D. M. Schwartz et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nature Reviews Rheumatology*, 12(1):25–36, 2016.

[44] M. D. Rosenblum et al. Treating human autoimmunity: current practice and future prospects. *Science translational medicine*, 4(125), 2012.

[45] J. H. Buckner. Antigen-specific immunotherapies for autoimmune disease. *Nature Reviews Rheumatology*, pages 1–10, 2024.

[46] R. Thomas et al. Overcoming obstacles in the development of antigen-specific immunotherapies for type 1 diabetes. *Frontiers in immunology*, 12:730414, 2021.

[47] J. Rana and M. Biswas. Regulatory T cell therapy: current and future design perspectives. *Cellular immunology*, 356:104193, 2020.

[48] P. Serra and P. Santamaria. Antigen-specific therapeutic approaches for autoimmunity. *Nature biotechnology*, 37(3):238–251, 2019.